Suzhou Ribobio Biotechnology Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 453

Employees

  • Stock Symbol
  • 06938

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $5.16
  • (As of Friday Closing)

Suzhou Ribobio Biotechnology General Information

Description

Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA therapeutics. The company's pipeline focuses on cardiovascular, metabolic, renal and liver diseases. Its pipeline includes RBD4059, RBD5044, RBD7007, RBD1119, RBD3103, SR122, SR126, RBD1016, SR112/SR113, among others. It has one reportable operating segment.

Contact Information

Website
www.ribolia.com
Formerly Known As
Suzhou Ruibo Biotechnology Co., Ltd.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Number 168 Yuanfeng Road, Yushan Town
  • Kunshan, Jiangsu 215300
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Number 168 Yuanfeng Road, Yushan Town
  • Kunshan, Jiangsu 215300
  • China
+86 0512

Suzhou Ribobio Biotechnology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Suzhou Ribobio Biotechnology Stock Performance

As of 20-Nov-2026, Suzhou Ribobio Biotechnology’s stock price is $5.16. Its current market cap is $873M with 169M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.16 $5.10 $4.72 - $12.29 $873M 169M 357K -$0.15

Suzhou Ribobio Biotechnology Financials Summary

As of 30-Jun-2026, Suzhou Ribobio Biotechnology has a trailing 12-month revenue of $66.4M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,057,618
Revenue 66,373 20,651 19,877 6
EBITDA (7,708) (30,226) (26,580) (52,536)
Net Income (24,243) (38,666) (37,649) (60,545)
Total Assets 414,868 120,029 89,157 101,042
Total Debt 79,885 78,618 58,750 58,508
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Suzhou Ribobio Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Suzhou Ribobio Biotechnology‘s full profile, request access.

Request a free trial

Suzhou Ribobio Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Suzhou Ribo Life Science Co Ltd is a biopharmaceutical company engaged in oligonucleotide R&D, with a focus on siRNA the
Drug Discovery
Kunshan, China
453 As of 2026

Gaithersburg, MD
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Suzhou Ribobio Biotechnology Competitors (43)

One of Suzhou Ribobio Biotechnology’s 43 competitors is Sirnaomics, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sirnaomics Formerly VC-backed Gaithersburg, MD
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Apeptico Formerly VC-backed Vienna, Austria
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
You’re viewing 5 of 43 competitors. Get the full list »

Suzhou Ribobio Biotechnology Patents

Suzhou Ribobio Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026233343-A1 Oligonucleotides, oligonucleotide conjugates, compositions, and uses Pending 07-May-2025
WO-2026228826-A1 Oligonucleotide, oligonucleotide conjugate, and composition and use Pending 30-Apr-2025
WO-2026228824-A1 Oligonucleotide, oligonucleotide conjugate, composition and use Pending 30-Apr-2025
WO-2026184535-A1 Oligonucleotide, oligonucleotide conjugate, composition, and use Pending 03-Mar-2025
WO-2026139046-A1 Oligonucleotide, oligonucleotide conjugate, composition, and use thereof Pending 26-Dec-2024
To view Suzhou Ribobio Biotechnology’s complete patent history, request access »

Suzhou Ribobio Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Suzhou Ribobio Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Suzhou Ribobio Biotechnology‘s full profile, request access.

Request a free trial

Suzhou Ribobio Biotechnology Investments (2)

Suzhou Ribobio Biotechnology’s most recent deal was a Later Stage VC with Azemidite for . The deal was made on 02-Jul-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Azemidite 02-Jul-2026 Later Stage VC Specialty Chemicals
Kunshan RiboQuark Pharmaceutical Technology 01-Sep-2012 Joint Venture Drug Discovery
To view Suzhou Ribobio Biotechnology’s complete investments history, request access »

Suzhou Ribobio Biotechnology ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Suzhou Ribobio Biotechnology’s complete esg history, request access »

Suzhou Ribobio Biotechnology FAQs

  • When was Suzhou Ribobio Biotechnology founded?

    Suzhou Ribobio Biotechnology was founded in 2007.

  • Where is Suzhou Ribobio Biotechnology headquartered?

    Suzhou Ribobio Biotechnology is headquartered in Kunshan, China.

  • What is the size of Suzhou Ribobio Biotechnology?

    Suzhou Ribobio Biotechnology has 453 total employees.

  • What industry is Suzhou Ribobio Biotechnology in?

    Suzhou Ribobio Biotechnology’s primary industry is Drug Discovery.

  • Is Suzhou Ribobio Biotechnology a private or public company?

    Suzhou Ribobio Biotechnology is a Public company.

  • What is Suzhou Ribobio Biotechnology’s stock symbol?

    The ticker symbol for Suzhou Ribobio Biotechnology is 06938.

  • What is the current stock price of Suzhou Ribobio Biotechnology?

    As of 20-Nov-2026 the stock price of Suzhou Ribobio Biotechnology is $5.16.

  • What is the current market cap of Suzhou Ribobio Biotechnology?

    The current market capitalization of Suzhou Ribobio Biotechnology is $873M.

  • What is Suzhou Ribobio Biotechnology’s current revenue?

    The trailing twelve month revenue for Suzhou Ribobio Biotechnology is $66.4M.

  • Who are Suzhou Ribobio Biotechnology’s competitors?

    Sirnaomics, WaVe Life Sciences, Intellia Therapeutics, Apeptico, and CRISPR Therapeutics are some of the 43 competitors of Suzhou Ribobio Biotechnology.

  • What is Suzhou Ribobio Biotechnology’s annual earnings per share (EPS)?

    Suzhou Ribobio Biotechnology’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process